Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Annovis Bio stock | $28.89

Learn how to easily invest in Annovis Bio stock.

Annovis Bio Inc is a biotechnology business based in the US. Annovis Bio shares (ANVS) are listed on the NYSE MKT and all prices are listed in US Dollars. Annovis Bio employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Annovis Bio

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Annovis Bio stock price (NYSE MKT: ANVS)

Use our graph to track the performance of ANVS stocks over time.

Annovis Bio shares at a glance

Information last updated 2021-10-18.
Latest market close$28.89
52-week range$4.20 - $132.00
50-day moving average $32.24
200-day moving average $49.99
Wall St. target price$70.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.20

Buy Annovis Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Annovis Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Annovis Bio price performance over time

Historical closes compared with the close of $28.89 from 2021-10-22

1 week (2021-10-15) 3.22%
1 month (2021-09-23) -18.46%
3 months (2021-07-23) -75.72%
6 months (2021-04-23) 25.61%
1 year (2020-10-23) 469.82%
2 years (2019-10-19) N/A
3 years (2018-10-19) N/A
5 years (2016-10-19) N/A

Annovis Bio financials

Gross profit TTM $0
Return on assets TTM -19.42%
Return on equity TTM -29.03%
Profit margin 0%
Book value $6.01
Market capitalisation $226.7 million

TTM: trailing 12 months

Shorting Annovis Bio shares

There are currently 370,374 Annovis Bio shares held short by investors – that's known as Annovis Bio's "short interest". This figure is 2% down from 378,091 last month.

There are a few different ways that this level of interest in shorting Annovis Bio shares can be evaluated.

Annovis Bio's "short interest ratio" (SIR)

Annovis Bio's "short interest ratio" (SIR) is the quantity of Annovis Bio shares currently shorted divided by the average quantity of Annovis Bio shares traded daily (recently around 209250.84745763). Annovis Bio's SIR currently stands at 1.77. In other words for every 100,000 Annovis Bio shares traded daily on the market, roughly 1770 shares are currently held short.

However Annovis Bio's short interest can also be evaluated against the total number of Annovis Bio shares, or, against the total number of tradable Annovis Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Annovis Bio's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Annovis Bio shares in existence, roughly 50 shares are currently held short) or 0.0671% of the tradable shares (for every 100,000 tradable Annovis Bio shares, roughly 67 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Annovis Bio.

Find out more about how you can short Annovis Bio stock.

Annovis Bio share dividends

We're not expecting Annovis Bio to pay a dividend over the next 12 months.

Annovis Bio overview

Annovis Bio, Inc. , a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. .

Frequently asked questions

What percentage of Annovis Bio is owned by insiders or institutions?
Currently 30.385% of Annovis Bio shares are held by insiders and 19.601% by institutions.
How many people work for Annovis Bio?
Latest data suggests 2 work at Annovis Bio.
When does the fiscal year end for Annovis Bio?
Annovis Bio's fiscal year ends in December.
Where is Annovis Bio based?
Annovis Bio's address is: 1055 Westlakes Drive, Berwyn, PA, United States, 19312
What is Annovis Bio's ISIN number?
Annovis Bio's international securities identification number is: US03615A1088
What is Annovis Bio's CUSIP number?
Annovis Bio's Committee on Uniform Securities Identification Procedures number is: 03615A108

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site